ÂÜŔňÂŇÂ×

Jennifer Cook joined the board of directors of Gyroscope Therapeutics in November 2020. She also serves on the boards of directors of Denali Therapeutics, BridgeBio Pharma and Ambys Medicines. Most recently, Jennifer was the Chief Executive Officer of GRAIL, a healthcare company focused on the early detection of cancer. Prior to joining GRAIL, she held a number of leadership positions during her 25-year tenure with Roche/Genentech, including leading Roche Pharmaceuticals’ European commercial business, Global Clinical Operations, U.S. and Global Product Portfolio Management, the U.S. Immunology and Ophthalmology Business Unit and Market Development. Jennifer holds a Bachelor’s Degree in Human Biology and a Master’s Degree in Biology from Stanford University, as well as a Master’s Degree in Business Administration from the Haas School of Business at the University of California, Berkeley.